Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.53 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614333 | 1.00 | MDM2 (0.53) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL12527832 | 1.00 | MDM2 (0.53) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL29398894 | 0.97 | MDM2 (0.54) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL29792115 | 0.94 | MDM2 (0.57) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL29547181 | 0.94 | MDM2 (0.57) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL29362301 | 0.94 | MDM2 (0.57) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL31681399 | 0.94 | MDM2 (0.57) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL6158363 | 0.94 | MDM2 (0.57) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL436024 | 0.94 | MDM2 (0.57) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL2288397 | 0.94 | MDM2 (0.57) | MDM2MDM4TP53KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116943-A1 | PROCESSES FOR SYNTHESIZING GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-30 | — | — | US | disclosed |
| EP-4706689-A2 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | Entrada Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2026-02-17 | — | — | US | disclosed |
| WO-2025264177-A1 | METHOD FOR CLEAVING PROTECTING GROUPS AND ORGANIC COMPOUNDS FROM SUPPORTS | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2025-12-26 | — | — | WO | disclosed |
| CN-120698907-A | Fmoc-Lys (Trt) -OH preparation method with side chain amino acid protection | 四川鸿日医药科技有限公司 | 2025-09-26 | — | — | CN | disclosed |
| CN-120698907-A | Fmoc-Lys (Trt) -OH preparation method with side chain amino acid protection | 四川鸿日医药科技有限公司 | 2025-09-26 | — | — | CN | disclosed |
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-12383605-B2 | Exenatide analog and use thereof | ANYGEN CO., LTD. (KR) | 2025-08-12 | — | — | US | disclosed |
| CN-115583987-B | Tumor targeting peptide aiming at carcinoembryonic antigen related adhesion molecule CEACAM and application thereof | 中国药科大学 | 2025-02-18 | — | — | CN | disclosed |
| WO-2025031383-A1 | BIFUNCTIONAL LINKER COMPOUND, ANTIBODY DRUG CONJUGATE, PREPARATION METHOD FOR ANTIBODY DRUG CONJUGATE, AND USE OF ANTIBODY DRUG CONJUGATE | 杭州爱科瑞思生物医药有限公司 | 2025-02-13 | — | — | WO | disclosed |
| WO-2022198231-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022198232-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-4058032-A1 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | Entrada Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-111675750-B | Tumor targeting peptide aiming at carcinoembryonic antigen related adhesion molecule CEACAM and application thereof | 中国药科大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-114981285-A | Synthesis of C-terminal protected fragment of peptide | 深圳市健元医药科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114805525-A | Preparation method of conopeptide | 深圳市健元医药科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-4031186-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | Seagen Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| CN-114728073-A | Selective release of drug from internalized conjugates of biologically active compounds | 思进股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383605-B2 | Exenatide analog and use thereof | GLP1R, IAPP, GIPR | MDM2 2891/4885MDM4 4237/4885TP53 4424/4885 |
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | MDM2 993/4885MDM4 1741/4885TP53 692/4885 |
| US-20260116943-A1 | PROCESSES FOR SYNTHESIZING GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES | GLP1R, PTMS, GCG | MDM2 3872/4885MDM4 2989/4885TP53 3874/4885 |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | CTH, VIP, CXCL10 | MDM2 1565/4885MDM4 2491/4885TP53 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.